Jan. 28 at 6:02 PM
$RVMD with acquisition chatter getting muted, I sense only direction is persistent downtrend near-term. Management likely leaked the fake AbbVie acquisition to WS Journal with hope to get desired MRK valuation, maybe >
$35B, but only that MRK walks away.
There are not many BP who could offer a price tag that would bring
$RVMD among world’s top 40 biotech without any revenhe yet. Current geopolitical situation may keep non-US BP away from bidding. Who knows RVMD may walk the same route as
$VKTX that lost ~2/3rd valuation.
https://companiesmarketcap.com/biotech/largest-companies-by-market-cap/
